Strides Pharma Science (NSE:STAR) E10: ₹64.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
71 GF Score
Price ₹999.00
GF Value ₹832.39
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Strides Pharma Science E10?

Strides Pharma Science NSE:STAR -0.48% 71 E10 is ₹64.48 as of Jun. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 71/100 and a GF Value™ of ₹832.39 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Strides Pharma Science's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹17.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹64.48 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Strides Pharma Science's average E10 Growth Rate was 6.10% per year. During the past 3 years, the average E10 Growth Rate was 42.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Strides Pharma Science was 42.90% per year. The lowest was 32.00% per year. And the median was 37.45% per year.

As of today (2026-08-11), Strides Pharma Science's current stock price is ₹999.00. Strides Pharma Science's E10 for the quarter that ended in Jun. 2026 was ₹64.48. Strides Pharma Science's Shiller PE Ratio of today is 15.49.

During the past 13 years, the highest Shiller PE Ratio of Strides Pharma Science was 23.39. The lowest was 5.01. And the median was 11.68.


Strides Pharma Science  (NSE:STAR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Strides Pharma Science's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=999.00/64.48
=15.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Strides Pharma Science was 23.39. The lowest was 5.01. And the median was 11.68.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Strides Pharma Science E10 Related Terms


Strides Pharma Science E10 Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science E10 Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.69 21.44 19.23 59.07 62.52

Strides Pharma Science Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.77 62.41 64.11 62.52 64.48

NSE:STAR vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Shiller PE Ratio falls into.


NSE:STAR
71GF Score
Strides Pharma Science Ltd NSE:STAR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strides Pharma Science's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.02/166.1454*166.1454
=17.020

Current CPI (Jun. 2026) = 166.1454.

Strides Pharma Science Quarterly Data

per share eps CPI Adj_EPS
201609 7.770 105.961 12.183
201612 5.010 105.196 7.913
201703 12.540 105.196 19.806
201706 0.060 107.109 0.093
201709 0.960 109.021 1.463
201712 9.540 109.404 14.488
201803 63.430 109.786 95.992
201806 -0.480 111.317 -0.716
201809 -1.340 115.142 -1.934
201812 32.760 115.142 47.271
201903 5.300 118.202 7.450
201906 0.410 120.880 0.564
201909 15.940 123.175 21.501
201912 10.480 126.235 13.793
202003 -22.770 124.705 -30.337
202006 11.560 127.000 15.123
202009 9.030 130.118 11.530
202012 4.220 130.889 5.357
202103 5.130 131.771 6.468
202106 -22.880 134.084 -28.351
202109 -18.120 135.847 -22.161
202112 -13.550 138.161 -16.295
202203 3.260 138.822 3.902
202206 -15.130 142.347 -17.659
202209 2.540 144.661 2.917
202212 -8.860 145.763 -10.099
202303 -1.040 146.865 -1.177
202306 -0.790 150.280 -0.873
202309 -14.540 151.492 -15.946
202312 5.420 152.924 5.889
202403 2.030 153.035 2.204
202406 363.960 155.789 388.155
202409 7.800 157.882 8.208
202412 9.550 158.323 10.022
202503 8.920 157.552 9.407
202506 10.810 159.755 11.242
202509 13.840 162.289 14.169
202512 21.920 163.281 22.305
202603 13.770 164.272 13.927
202606 17.020 166.145 17.020

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹64.48 mean?
Strides Pharma Science (NSE:STAR) has a E10 of ₹64.48 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's E10 too high?
Strides Pharma Science's current E10 is ₹64.48. Overall, Strides Pharma Science has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's E10 compare to ZTS?
Strides Pharma Science's E10 of ₹64.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current E10 is ₹64.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹832.39, compared to a current price of ₹999.00 — trading 20% above its estimated fair value. The current E10 is ₹64.48. Strides Pharma Science's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current E10 is ₹64.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹999.00 is trading 20% above its estimated GF Value™ of ₹832.39. GuruFocus considers Strides Pharma Science to be Modestly Overvalued.

Key valuation signals for NSE:STAR:

  • E10: ₹64.48
  • GF Value™: ₹832.39 vs. price of ₹999.00 (20% above fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
71GF Score

Get the complete analysis for NSE:STAR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹999.00
Price
₹832.39
GF Value